These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 25520071

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
    Navari RM.
    Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
    [Abstract] [Full Text] [Related]

  • 9. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Navari RM, Nagy CK, Gray SE.
    Support Care Cancer; 2013 Jun; 21(6):1655-63. PubMed ID: 23314603
    [Abstract] [Full Text] [Related]

  • 10. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
    Navari RM.
    Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2738-46. PubMed ID: 25838122
    [Abstract] [Full Text] [Related]

  • 11. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J.
    Ugeskr Laeger; 2007 Feb 26; 169(9):799-805. PubMed ID: 17355844
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ.
    Hosp Pract (1995); 2015 Feb 26; 43(4):226-34. PubMed ID: 26308912
    [Abstract] [Full Text] [Related]

  • 16. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS.
    Support Care Cancer; 2007 Nov 26; 15(11):1285. PubMed ID: 17375339
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
    Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, Tanaka A, Takahashi N, Takekuma M, Hihara H, Ichikawa Y, Itonaga Y, Hirakawa T, Nasu K, Miyagi K, Murakami J, Ito K.
    Support Care Cancer; 2016 Feb 26; 24(2):675-682. PubMed ID: 26130365
    [Abstract] [Full Text] [Related]

  • 19. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 26; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 20. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug 26; 11(4):481-8. PubMed ID: 21711119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.